Norden Group LLC Has $149,000 Stock Holdings in Organon & Co. $OGN

Norden Group LLC lessened its stake in Organon & Co. (NYSE:OGN) by 23.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,434 shares of the company’s stock after selling 4,795 shares during the quarter. Norden Group LLC’s holdings in Organon & Co. were worth $149,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. GAMMA Investing LLC increased its holdings in shares of Organon & Co. by 22.4% in the second quarter. GAMMA Investing LLC now owns 5,645 shares of the company’s stock valued at $55,000 after purchasing an additional 1,034 shares in the last quarter. SBI Securities Co. Ltd. increased its stake in shares of Organon & Co. by 17.6% in the 1st quarter. SBI Securities Co. Ltd. now owns 7,653 shares of the company’s stock valued at $114,000 after buying an additional 1,145 shares during the period. Handelsbanken Fonder AB raised its position in shares of Organon & Co. by 1.5% during the first quarter. Handelsbanken Fonder AB now owns 81,565 shares of the company’s stock worth $1,215,000 after acquiring an additional 1,200 shares during the last quarter. Xponance Inc. lifted its stake in shares of Organon & Co. by 15.2% during the first quarter. Xponance Inc. now owns 13,828 shares of the company’s stock valued at $206,000 after acquiring an additional 1,823 shares during the period. Finally, Brown Advisory Inc. lifted its stake in shares of Organon & Co. by 6.5% during the first quarter. Brown Advisory Inc. now owns 30,174 shares of the company’s stock valued at $449,000 after acquiring an additional 1,835 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

Shares of NYSE:OGN opened at $10.21 on Friday. The stock has a market capitalization of $2.65 billion, a P/E ratio of 3.79, a P/E/G ratio of 0.93 and a beta of 0.60. Organon & Co. has a 1-year low of $8.01 and a 1-year high of $19.41. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. The business has a 50-day moving average price of $9.77 and a two-hundred day moving average price of $10.54.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. Organon & Co.’s revenue was down .8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. Equities analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Friday, August 15th were given a dividend of $0.02 per share. The ex-dividend date was Friday, August 15th. This represents a $0.08 annualized dividend and a dividend yield of 0.8%. Organon & Co.’s payout ratio is presently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.